Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

unknown117%
completed350%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
unknownphase_2

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease

NCT05811000
terminatedphase_1

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
terminatedphase_1

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
completedphase_1

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
completedphase_1

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

NCT02051335
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05811000Phase 2

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease

Unknown
NCT02918266Phase 1

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Terminated
NCT02769065Phase 1

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Terminated
NCT03030105Phase 1

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Completed
NCT02051335Phase 1

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Completed
NCT00911807Phase 2

Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6